

HEK293 Rat mGluR5 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0153C | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
mGluR5 is a widely expressed metabotropic glutamate receptor in the central nervous system. It is primarily located on the surface of neurons, where it regulates synaptic plasticity and neurotransmission to participate in key physiological processes such as learning and memory. It also serves as an important target for drug development in neurological disorders including Fragile X syndrome, Parkinson's disease, anxiety, and pain. Currently, both positive and negative allosteric modulators targeting this receptor have become a research focus for therapeutic strategies.
Screeningbio’s HEK293/Rat mGluR5 cell line overexpress mGluR5 and is designed to detect increases in intracellular Calcium flux signal in response to agonist stimulation of the receptor. Molecular Devices Calcium 6 kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Rat |
HGNC Symbol | mGluR5 |
Accession Number | NM_017012 |
Parental Line | HEK293 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
![HEK293/Rat mGluR5 Agonist Assay. HEK293/Rat mGluR5 cells were treated with the reference agonist L-Glu. The assay was run based on FLIPR Calcium 6 Assay protocol. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 values were determined, using GraphPad Prism software.](https://static.wixstatic.com/media/cbf7de_39cc6ba4c0384baa93dc8e97119a6480~mv2.png/v1/fill/w_75,h_75,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/cbf7de_39cc6ba4c0384baa93dc8e97119a6480~mv2.png)
Target Background
mGluR5 is a widely expressed metabotropic glutamate receptor in the central nervous system. It is primarily located on the surface of neurons, where it regulates synaptic plasticity and neurotransmission to participate in key physiological processes such as learning and memory.
It also serves as an important target for drug development in neurological disorders including Fragile X syndrome, Parkinson's disease, anxiety, and pain. Currently, both positive and negative allosteric modulators targeting this receptor have become a research focus for therapeutic strategies.